No black box warning on record for Dantrolene Sodium

As of the latest FDA labeling reviewed, Dantrolene Sodium (DANTROLENE SODIUM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dantrolene Sodium medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS It is important to recognize that fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. At the start of dantrolene sodium therapy, it is desirable to do liver function studies (SGOT, SGPT, alkaline phosphatase, total bilirubin) for a baseline or to establish whether there is pre-existing liver disease. If baseline liver

No black box warning on record for Dantrolene Sodium

Other warnings & precautions

WARNINGS It is important to recognize that fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. At the start of dantrolene sodium therapy, it is desirable to do liver function studies (SGOT, SGPT, alkaline phosphatase, total bilirubin) for a baseline or to establish whether there is pre-existing liver disease. If baseline liver

Dantrolene Sodium Black Box Warning

No black box warning on record for Dantrolene Sodium

Other warnings & precautions

Dantrolene Sodium Black Box Warning

No black box warning on record for Dantrolene Sodium

Other warnings & precautions